341 Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC)
oleh: Lawrence Karsh, Sreenivas Adurthi, Rahul Aggarwal, Mark Linch, Dan Costin, Jingsong Zhang, Paul Monk, Stefani Corsi-Travali, Adedayo Adedoyin
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2020-11-01 |
Deskripsi
No description available for this item.